{"id":14354,"date":"2023-08-31T15:32:00","date_gmt":"2023-08-31T07:32:00","guid":{"rendered":"https:\/\/flcube.com\/?p=14354"},"modified":"2024-11-23T16:30:51","modified_gmt":"2024-11-23T08:30:51","slug":"novo-nordisk-acquires-embark-biotech-to-boost-obesity-and-cardiometabolic-drug-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=14354","title":{"rendered":"Novo Nordisk Acquires Embark Biotech to Boost Obesity and Cardiometabolic Drug Development"},"content":{"rendered":"\n

Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO<\/a>) has announced the purchase of compatriot Embark Biotech, marking a significant step in the discovery and development of drug candidates for obesity and related comorbidities. The acquisition allows Novo Nordisk to incorporate Embark\u2019s lead metabolic program for cardiometabolic diseases, including obesity. The program involves a molecule that suppresses appetite, increases energy expenditure, and enhances insulin sensitivity, stemming from an early collaboration with Novo Nordisk.<\/p>\n\n\n\n

Options for Asset Acquisition and Financial Terms<\/strong>
Novo Nordisk also retains the option to acquire selected assets across indications such as obesity and type 2 diabetes (T2D). As part of the deal, the company is paying EUR 15 million upfront to Embark shareholders, with the potential for additional payments of up to EUR 456 million for achieving development, regulatory, and commercial milestones.<\/p>\n\n\n\n

Strategic Expansion in Cardiometabolic Disorders<\/strong>
According to Fineline Info & Tech<\/a> data, this announcement coincides with Novo Nordisk’s entry into an agreement to acquire Inversago Pharma, a specialist in cardiometabolic disorders. This strategic move highlights Novo Nordisk’s commitment to expanding its portfolio and leadership in the treatment of obesity and related metabolic conditions.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced the purchase of compatriot Embark Biotech,…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[30,39,2292,148,860,86],"class_list":["post-14354","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-biotech","tag-diabetes","tag-embark-biotech","tag-novo-nordisk","tag-nyse-nvo","tag-obesity"],"yoast_head":"\nNovo Nordisk Acquires Embark Biotech to Boost Obesity and Cardiometabolic Drug Development - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced the purchase of compatriot Embark Biotech, marking a significant step in the discovery and development of drug candidates for obesity and related comorbidities. The acquisition allows Novo Nordisk to incorporate Embark\u2019s lead metabolic program for cardiometabolic diseases, including obesity. The program involves a molecule that suppresses appetite, increases energy expenditure, and enhances insulin sensitivity, stemming from an early collaboration with Novo Nordisk.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=14354\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk Acquires Embark Biotech to Boost Obesity and Cardiometabolic Drug Development\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=14354\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-31T07:32:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-23T08:30:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14354#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14354\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novo Nordisk Acquires Embark Biotech to Boost Obesity and Cardiometabolic Drug Development\",\"datePublished\":\"2023-08-31T07:32:00+00:00\",\"dateModified\":\"2024-11-23T08:30:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14354\"},\"wordCount\":203,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biotech\",\"Diabetes\",\"Embark Biotech\",\"Novo Nordisk\",\"NYSE: NVO\",\"Obesity\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=14354#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14354\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=14354\",\"name\":\"Novo Nordisk Acquires Embark Biotech to Boost Obesity and Cardiometabolic Drug Development - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-08-31T07:32:00+00:00\",\"dateModified\":\"2024-11-23T08:30:51+00:00\",\"description\":\"Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced the purchase of compatriot Embark Biotech, marking a significant step in the discovery and development of drug candidates for obesity and related comorbidities. The acquisition allows Novo Nordisk to incorporate Embark\u2019s lead metabolic program for cardiometabolic diseases, including obesity. The program involves a molecule that suppresses appetite, increases energy expenditure, and enhances insulin sensitivity, stemming from an early collaboration with Novo Nordisk.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14354#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=14354\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14354#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk Acquires Embark Biotech to Boost Obesity and Cardiometabolic Drug Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk Acquires Embark Biotech to Boost Obesity and Cardiometabolic Drug Development - Insight, China's Pharmaceutical Industry","description":"Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced the purchase of compatriot Embark Biotech, marking a significant step in the discovery and development of drug candidates for obesity and related comorbidities. The acquisition allows Novo Nordisk to incorporate Embark\u2019s lead metabolic program for cardiometabolic diseases, including obesity. The program involves a molecule that suppresses appetite, increases energy expenditure, and enhances insulin sensitivity, stemming from an early collaboration with Novo Nordisk.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=14354","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk Acquires Embark Biotech to Boost Obesity and Cardiometabolic Drug Development","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=14354","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-08-31T07:32:00+00:00","article_modified_time":"2024-11-23T08:30:51+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=14354#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=14354"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novo Nordisk Acquires Embark Biotech to Boost Obesity and Cardiometabolic Drug Development","datePublished":"2023-08-31T07:32:00+00:00","dateModified":"2024-11-23T08:30:51+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=14354"},"wordCount":203,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biotech","Diabetes","Embark Biotech","Novo Nordisk","NYSE: NVO","Obesity"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=14354#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=14354","url":"https:\/\/flcube.com\/?p=14354","name":"Novo Nordisk Acquires Embark Biotech to Boost Obesity and Cardiometabolic Drug Development - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-08-31T07:32:00+00:00","dateModified":"2024-11-23T08:30:51+00:00","description":"Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced the purchase of compatriot Embark Biotech, marking a significant step in the discovery and development of drug candidates for obesity and related comorbidities. The acquisition allows Novo Nordisk to incorporate Embark\u2019s lead metabolic program for cardiometabolic diseases, including obesity. The program involves a molecule that suppresses appetite, increases energy expenditure, and enhances insulin sensitivity, stemming from an early collaboration with Novo Nordisk.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=14354#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=14354"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=14354#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk Acquires Embark Biotech to Boost Obesity and Cardiometabolic Drug Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14354","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14354"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14354\/revisions"}],"predecessor-version":[{"id":14384,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14354\/revisions\/14384"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14354"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14354"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14354"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}